Cannabis

MDMA for PTSD - MDMA, the active ingredient in the party drug ecstasy, is being touted as a game-changing treatment for post-traumatic stress disorder. It is being trialed in America—and for one army veteran the drug has been a life-saver - this is a truly marvelous video  EU is ...read more

ARTICLE first printed here It’s been 5 months now since the coronavirus outbreak started. Due to the lockdown policy that was implemented worldwide, people had to come up with ideas to keep themselves healthy, safe and entertained indoors. Needless to say, people had adapted to ...read more

Cannabis in Germany - A great article by my good friend Alfredo Pascual (Link) - Germany imported 1,032 kilograms (2,275 pounds) of medical cannabis flower for pharmacy dispensing through March 6, an amount that indicates little if any growth versus the average cannabis imported ...read more

The marvel of the cannabis plant is endless - here is an excerpt I came across this week speaking about the cannabis Sativa plant. The plant is a wonder of nature, a factory for brain-altering chemicals unlike any the world has ever seen. But there is a tremendous amount of ...read more

CBD and anxiety - It is very likely that CBD will eventually become a treatment for anxiety (amongst other things). A study conducted by researchers at the Johns Hopkins University School of Medicine and published in the Journal of Substance Abuse Treatment asked 200 people with ...read more

A note on psychedelics - Before they were banned about a half-century ago, psychedelic drugs like LSD and psilocybin showed promise for treating conditions including alcoholism and some psychiatric disorders. Researchers say it's time for regulators, scientists, and the public to ...read more

Based on limited time, I’ve postponed top-level insights this week. I do know to acknowledge the great work the ACI is doing in the U.K. to create a CBD Safety Certification programme. I’ve previously commented on the need for standards for CBD products in emerging markets. The ...read more

Differentiated delivery formats are still an area of uncharted territory amongst cannabis companies. There are several products in the market with minimal pharmacokinetic data to support bi-availability, yet this has not appeared to be an issue to the growing number of patients ...read more

This week I read that overall U.S. sale of legalised cannabis was expected to reach $13.6 billion throughout 2019, up 32% from 2018’s total of $10.3 billion. I wonder if the economic slowdown which COVID-19 has created will make cannabis legalisation at the federal and state ...read more

Once again, the WHO is expecting to delay the vote affecting the scheduling of THC and CBD. At a time where CBD across the EU is under fire, a firm position from the WHO would be welcomed by the industry. However, countries have welcomed the expected postponement of the vote ...read more

The coronavirus outbreak in China likely will benefit American hemp companies that compete with Chinese suppliers on the global and domestic markets. And this newest issue underscores the vulnerabilities in the global marketplace that vape and other cannabis and hemp companies ...read more

Europe offers growth opportunities for the next wave of cannabis organisations. The UK, Germany, Italy and the Netherlands already have legal systems in place for medicinal cannabis and France and Spain are currently reviewing key legislative reform to align themselves with ...read more

Brazil and New Zealand share common fates as the two countries open up patients' ability to access medical cannabis. Both countries emphasise GMP only products, meaning companies that intend to import into these countries require manufacture under EUGMP (or equivalent). This is ...read more

3,682 medicinal cannabis prescriptions were approved via SAS Category B in December 2019. Prescriptions throughout 2019, increased month on month excluding November which dropped by 190 prescriptions compared to October. The only drop in prescriptions recorded before this was in ...read more

The growing concern over calories and hangovers is driving more millennials to replace alcohol with cannabis in their social life. A recent study by Future research found US millennials drink far less alcohol than previous generations: The percentage of college students who drink ...read more

Cannabis production may be too risky and restrictive for new cultivation companies. High input costs, unstable genetics, and a steep learning curve lead to non-viable output costs for cannabis companies. The new entrants into the market are also seeing high barriers to entry ...read more